Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular…
$15.33-1.10%
报价 2026-11-13
市值
$1.36B
EV
$2.7B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -65.4%
$15.24$44.26
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MLYSMineralys Therapeutics, Inc. | $1.36B | -1.1% | – | 0% | – | – | – | |
| SRRKScholar Rock Holding Corporation | $5.27B | +0.1% | +8150.0% | 0% | – | – | – | |
| ADPTAdaptive Biotechnologies Corporation | $4.7B | -1.5% | +15.5% | 75.3% | – | – | – | |
| IDYAIDEAYA Biosciences, Inc. | $3.08B | +1.1% | -79.1% | 99.5% | – | – | – | |
| ZLABZai Lab Limited | $2.78B | -5.5% | – | 56.5% | – | – | – | |
| BEAMBeam Therapeutics Inc. | $2.36B | -5.0% | +6.9% | 100% | – | – | – | |
| RXRXRecursion Pharmaceuticals, Inc. | $1.98B | -4.4% | -36.9% | -49.8% | – | – | – | |
| AGIOAgios Pharmaceuticals, Inc. | $1.89B | -0.5% | +295.0% | 87.9% | – | – | – | |
| 同行中位数 | – | – | +11.2% | 75.3% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。